Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1855, Issue 2, Pages 144-154Publisher
ELSEVIER
DOI: 10.1016/j.bbcan.2015.01.001
Keywords
5-Hydroxymethylcytosine; DNA methylation; Cancer; TET; IDH
Categories
Funding
- Netherlands Institute for Regenerative Medicine (NIRM) [DFES1029161]
- ERA-NET/TRANSCAN/FP7 [KUN2013-6395]
Ask authors/readers for more resources
The epigenetic mark 5-hydroxymethylcytosine (5hmC) has gained interest since 2009, when it was discovered that Ten-Eleven-Translocation (TET) proteins catalyze the conversion of 5-methylcytosine (5mC) into 5hmC. This conversion appears to be an intermediate step in the active DNA demethylation pathway. Factors that regulate DNA hydroxymethylation are frequently affected in cancer, leading to deregulated 5hmC levels. In this review, we will discuss the regulation of DNA hydroxymethylation, defects in this pathway in cancer, and novel therapies that may correct deregulated (hydroxy)methylation of DNA. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
